Fennec Pharmaceuticals Inc. (FENC) Cash Flow Statement

The extreme variance in the OCF/NI ratio suggests that reported net income is a poor proxy for the company's actual cash health. Investors should monitor whether these fluctuations are driven by lumpy revenue recognition or timing differences in distributor payments, as the lack of consistent conversion complicates the assessment of core operational viability.

The erratic FCF performance suggests that the company's cash burn is highly sensitive to quarterly operational shifts rather than a steady, predictable business model. This instability warrants further investigation into whether the company can achieve a sustainable cash-flow-positive state without further external capital injections.

The significant reliance on working capital movements to fund operations appears to mask the underlying cash burn of the commercial organization. This pattern implies that the company's cash position is highly vulnerable to the timing of hospital procurement cycles and distributor inventory stocking, which may not reflect true patient demand.